메디포스트

078160KOSDAQ기초 의약물질 제조업

39.2 / 100

Reference Date: 2026-04-13

Financial Score9.5 / 40

News Sentiment11.7 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Declined 10.2% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Medipost operates three main business segments: umbilical cord blood banking, stem cell therapeutics (Cartistem), and health functional foods. In 2024, the company achieved a record sales revenue of 70.7 billion won, driven by strong performance in its cord blood banking division, which holds the top market share domestically, and its stem cell therapeutics division expanding global clinical trials.

Number of Employees

684people

Average Salary

61.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 33.454.0Point

PBR

3.18Industry Average 2.031.0Point

1.6x industry avg (risky)

ROE

-34.23Industry Average -4.293.5Point

8.0x industry avg (excellent)

Debt Ratio

33.95Industry Average 6.610.0Point

5.1x industry avg (risky)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼66.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.2% (declining, 3yr)

Detailed News Sentiment

6 totalPositive 0Neutral 0Negative 2Average Sentiment Score 40

Negative
메디포스트, 지난해 영업손실 679억…"글로벌 임상 비용 증가"
메디포스트는 지난해 연결 기준 영업손실 679억원을 기록했는데, 이는 줄기세포치료제 '카티스템'의 해외 대규모 후기 임상 진행에 따른 비용 증가가 주된 원인이다.
Negative
메디포스트, 매출 전년 대비 4.2%↑…"글로벌 임상 지속"
메디포스트는 해외 대규모 후기 임상 진행에 따른 비용 증가로 지난해 연결 기준 영업손실이 확대되었으나, 별도 기준으로는 국내 사업 성장세에 힘입어 흑자 기조를 유지했다.

Detailed Momentum

52-week position6.0Point

52w upper range (68%)

Current 20,250Won52-week high 25,95052-week low 8,100

1-month return1.0Point

1m -10.20% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral정기주주총회결과2026-03-27
Neutral주주총회집중일개최사유신고2026-03-20
Neutral감사보고서제출2026-03-19
Neutral사업보고서 (2025.12)2026-03-19
Neutral기업설명회(IR)개최2026-03-16